Amylyx Pharmaceuticals, Inc. (AMLX): M&A transaction — Amylyx completes acquisition of Avexitide from Eiger for $35.1M

Amylyx Pharmaceuticals, Inc.

Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.
Sale approved by U.S. Bankruptcy Court for Northern District of Texas on June 26, 2024; closed July 9, 2024.
Amylyx will handle development, manufacture, and commercialization of Avexitide post-closing.
Transaction follows Asset Purchase Agreement dated June 21, 2024, as previously disclosed.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Amylyx Pharmaceuticals, Inc. completed an acquisition involving Eiger BioPharmaceuticals, Inc. for $35.1 million (closed 2024-07-09).

Action: acquisition
Counterparty: Eiger BioPharmaceuticals, Inc.
Consideration: $35.1 million
Closing: 2024-07-09

Exact text from the filing

the Company agreed to acquire substantially all of the Seller’s rights, title and interests in, to and under those assets and interests used by the Seller in the development, manufacture and commercialization of Avexitide for $35.1 million

View on SEC.gov

Browse all m&a transactions →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-177000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.